On the other hand, USP9X overexpression promotes centrosome amplification and carcinogenesis in breast carcinomas [6] and resistance to mitotic-spindle-poison-containing chemotherapy in human B-cell lymphoma [29]. Here, USP9X is linked to B-cell non-Hodgkin lymphoma.